Binding reactions between human growth hormone (hGH) and its receptor provide a detailed account of how a polypeptide hormone activates its receptor and more generally how proteins interact. Through high-resolution structural and functional studies it is seen that hGH uses two different sites (site 1 and site 2) to bind two identical receptor molecules. This sequential dimerization reaction activates the receptor, presumably by bringing the intracellular domains into close proximity so they may activate cytosolic components. As a consequence of this mechanism it is possible to build antagonists to the receptor by introducing mutations in hGH that block binding at site 2 and to build even more potent antagonists by combining these with mutants that enhance binding at site 1. Alanine-scanning mutagenesis of all contact residues at the site 1 interface shows that only a small and complementary set of side chains clustered near the center of the interface affects binding. The most important contacts are hydrophobic, and these are surrounded by polar and charged interactions of lesser importance. Kinetic analysis shows for the most part that the important side chains function to maintain the complex, not to guide the hormone to the receptor. Hormoneinduced homodimerization or heterodimerization reactions are turning out to be pervasive mechanisms for signal transduction. Moreover, the molecular recognition principles seen in the hGHreceptor complex are likely to generalize to other protein-protein complexes.
How do hormones find their receptors?
Once there, what forces allow the hormone to bind? How does hormone binding lead to receptor activation? Most biological processes are regulated or structured by these reactions involving noncovalent associations. Thus, an understanding of how hormones bind their receptors is broadly relevant to many other molecular recognition events in biology.
This minireview will begin to address these questions from the perspective of a complex between human growth hormone (hGH) and the extracellular domain of its receptor, called the hGHbp (for general reviews see refs. 1 and 2). This complex has been intensively studied by mutational and structural methods for several reasons. First, the pharmacology of hGH is rather complex (3) . For example it can bind and activate at least two different cloned receptors, the hGH (4) and prolactin receptors (5) . Moreover, hGH is a member of the cytokine receptor superfamily (6) , and thus an understanding of how it binds its receptor may shed light on the entire family. Finally, it is hoped that through a detailed understanding of the structure and chemistry involved in the binding reaction, one would be in a better position to rationally design small molecules that could mimic the large interfaces that are typical of protein-protein complexes.
Basic Methods and Approaches
Any detailed structural and functional analysis is greatly facilitated by having an abundant and recombinant source of the component molecules. We were particularly fortunate to have Escherichia coli secretion systems for both hGH (7) and the hGHbp (8) . These expression systems allowed rapid and high-level production of these proteins in forms that interacted with virtually the same affinity as those from natural or recombinant mammalian sources (K d Ϸ 0.3 nM).
Determining the stoichiometry of the complex is fundamental to characterizing any binding reaction. Initially, we presumed that growth hormone bound to only one receptor in solution, because Scatchard analysis from an RIA showed a 1:1 stoichiometry. As it turned out, however, the receptor antibody (MAb5, ref. 9) used to precipitate the hGH⅐hGHbp complex sterically excluded the second receptor molecule from binding (10) . This was a blessing in disguise because more complex stoichiometries (such as the 1:2 stoichiometry that was later discovered) would have made interpretation more difficult than was the case for the single interface that was initially discovered (11, 12) .
A variety of biophysical methods were used to determine that the stoichiometry of the hGH⅐hGHbp complex in solution was 1:2 (10). One of the most powerful was titration calorimetry, which showed that the binding reaction was complete when 1 equivalent of hormone was added to 2 equivalents of the hGHbp. Gel filtration showed that mixtures containing 1 equivalent of hGH (22 kDa) plus 2 equivalents of hGHbp (28 kDa) ran as a single peak (Ϸ75 kDa) with no evidence of excess free components. SDS͞PAGE and densitometry of the 75-kDa peak showed it had a composition of one hGH molecule per two hGHbp molecules. Furthermore, crystals of the complex were obtained and when dissociated gave a composition of one hGH molecule per two hGHbp molecules (10, 13) .
Two mutagenesis strategies, homologscanning (11) and alanine-scanning (12) , were employed to define binding determinants in the hGH and the hGHbp (for review see ref. 14) . Initially, these studies were performed without the aid of the structures of the complex or of the individual components. In homolog-scanning, segments (7-30 residues long) derived from nonbinding homologs, such as prolactin or porcine growth hormone, were substituted into hGH. From the set of segment-substituted molecules that disrupted binding affinity, we could infer regions of the hormone that may contain binding determinants. These regions were then subjected to alanine-scanning mutagenesis in which each residue within the disruptive segment was replaced by alanine and the consequences for binding affinity were measured. In this way the role of side-chain atoms beyond the ␤-carbon could be assessed. A panel of monoclonal antibodies that reacted with the native components, but not the unfolded forms, were used to verify that these mutations did not affect the overall fold of the protein.
Two different assays were used to determine the effects of hGH mutants on binding. Using MAb5 to precipitate 1:1 complexes, we found a patch of mutations that disrupted binding to a region we called site 1. The second assay followed the hGH-induced dimerization of hGHbp molecules in solution by the quenching of a fluorescent tag placed near the C terminus of the hGHbp (10) . The patch of alanine mutations outside the site 1 patch that had reduced affinity in this assay we called site 2.
The solution of the x-ray structure of the 1:2 hGH⅐hGHbp complex (15) perAbbreviations: hGH, human growth hormone; hGHbp, the extracellular domain of the hGH receptor; variant proteins are indicated by the single-letter code for the wild-type residue followed by its position in the mature protein sequence and the substituted residue. mitted all the mutational and biophysical data to be interpreted in structural context for the first time. This was an enormous advance. Not only did it reveal the 1:2 nature of the complex and the structures of the bound components, it identified all the contact residues at the two hormone-receptor interfaces as well as showing that the receptors contact each other (Fig. 1) .
Side Chains on the hGH Mostly Affect Dissociation, Not Association
Binding affinity can be considered a simple balance of two reactions, association and dissociation (Eq. 1).
What role do contact side chains play in determining on-rate (k on ) or off-rate (k off )? To address this question we focused on the binding of hGH via site 1 to the first bound receptor.
To study the kinetics of binding we used a BIAcore (Pharmacia) (16) . This device has a flow cell with a gold film layered on the outside. Attached to the gold film is a layer of dextran fibers which extend into the flow cell to which we covalently attached the hGHbp (17) . As hGH flows through the cell, it binds to the immobilized hGHbp. This causes a change in refractive index of the medium which is detected by a change in surface plasmon resonance of the gold film (called resonance units or RU). The stoichiometry of binding can be calculated from the total change in RU, as this is related to the mass bound to the chip. On-rates are measured by the rate of change in RU as a function of hGH concentration. Off-rates are determined from rate of the decrease in RU upon release of hGH from a saturated chip.
To study the binding of hGH at site 1 without the complication of forming 1:2 complexes, or binding through site 2, we prepared a receptor that could bind hGH only at site 1 (17) . This was done by introducing a mutation in the receptor stem region (S201C) and fixing this by a disulfide linkage to the flow chip. Not only did this prevent receptor dimerization, it also presented the hGHbp in a uniform fashion to the hormone. Using this construction, we determined a stoichiometry of binding of hGH⅐hGHbp of 0.84, a k on of 3 ϫ 10 5 s Ϫ1 ⅐M
Ϫ1
, and a k off of 2.7 ϫ 10
. These values were virtually the same for a variant of hGH (G120R) which is blocked in binding to a second receptor by a mutation in site 2, indicating that the measured kinetic parameters reflected binding at site 1. Moreover, the affinity constant was in close agreement with that determined by RIA using MAb5.
The side chains of 31 residues of hGH become buried to various degrees upon binding the first receptor (15) . We converted each of these residues to alanine and measured their on-rates and off-rates (17) . The largest effects were for six mutants (P61A, R64A, K172A, T175A, F176A, and R178A) which individually caused a 5-to 30-fold increase in off-rate, but only a 1.1-to 2.5-fold decrease in on-rate. The subtle effects on the on-rate were best correlated to changes in the electrostatics of the binding site. For example, the largest decreases in on-rate were for mutating positively charged residues, and the largest increases in on-rate (up to 1.5-fold) were for mutating two negatively charged groups (E65A and E174A) at the binding site.
Northrup and Erickson (18) have noted that protein-protein association generally occurs at rates that are 10 3 to 10 4 times faster than would be expected from simple considerations of collision frequencies (Ϸ10 9 s Ϫ1 ⅐M
) and strict orientation effects that assume productive binding occurs only when the molecules collide within 2 Å of their final binding site. These orientation effects are predicted to reduce the rate of productive collisions by Ϸ10 6 to produce on-rates of Ϸ10 3 s Ϫ1 ⅐M
. They argue that long-lived collisions, or Brownian diffusion, would greatly accelerate the association. In other words, when the proteins collide, they do not diffuse away immediately but roll on one another and thereby sample much more surface area than would be the case for a single elastic collision. They suggest that association rates between proteins are dominated by considerations of diffusion events alone.
We can conclude that only a small set of side chains modulate these effects on the affinity between hGH and the hGHbp and that their major role is to slow the off-rate. This suggests there are many paths to getting the hormone to the receptor. The role of side chains is to keep the hormone bound once it has reached the binding site, not to get it there in the first place. Although electrostatic interactions can subtly influence the rate of association of the hGH to the receptor, association is controlled by diffusion, which is independent of the side-chain composition of the interface. Thus, the hormone finds its receptor mostly by a random but rapid collision process; the side chains function to keep it bound once it has reached its receptor target.
Binding Affinity Is Maintained by a Small Cluster of Contact Residues
From the ratio of on-and off-rates, we calculated the effects of the contact side chains in site 1 on affinity. From this it became clear that only a small set of the buried side chains were necessary for tight binding affinity. In fact, alanine substitutions at only 8 of the 31 positions (K41, L45, P61, R64, K172, T175, F176, and R178) could account for Ϸ85% of the binding energy. These formed two small patches near the center of the contact interface that we call the functional epitope (Fig. 2) .
A similar analysis (19, 20) was performed on the receptor side, where 33 side chains become buried at the interface. Each of these residues (except G168 and the C108-C122 disulfide) were converted to alanine, and affinities of the mutated receptors to hGH were measured by RIA. Nine of these residues (R43, E44, I103, W104, I105, P106, I164, D165, and W169) could account for virtually all the binding affinity. These residues cluster at the center of the contact interface (Fig. 2) .
What structural features explain why some residues are important while others are not? The functionally important residues are those located near the center of the contact epitope and contact those found to be functionally important residues on the other side. The most critical interactions tend to be well-packed hydrophobic contacts. This is obvious on the receptor side, where W104 and W169 are by far the most important residues. The aliphatic portions of important charged and polar side chains from hGH, such as D171, K172, and T175, pack against the tryptophans on the receptor. No (or few) buried waters are seen between the functional epitopes (20) .
The unimportant residues tend toward the periphery of the contact or structural epitope. These are often polar and incompletely dehydrated. Thus, bridging water molecules are seen between polar or charged contact residues in regions of the contact interface that are less important. The extent of side-chain burial, or number of van der Waals contacts on their own, are generally weak predictors of relative effects on affinity when side chains are converted to that of alanine (17, 20) . These correlations are much better, however, when one considers only the burial of well-packed hydrophobic side chains.
The hGH Receptor Is Activated by Sequential Dimerization
Receptor oligomerization is a common, if not pervasive, means by which extracellular hormones transmit their signals to the inside of a cell without ever passing through the membrane (for reviews see refs. [21] [22] [23] . By a hormone simply bringing together two or more transmembrane membrane receptors, the intracellular domains of these can be juxtaposed so that they may interact with other cellular components or catalyze a reaction (typically protein phosphorylation).
The most striking aspect of the hGHreceptor complex is that one hormone binds and dimerizes two receptors. Mutational and biophysical studies (10, 24) have shown that these sites do not react randomly with the receptor but do so in a sequential fashion (Fig. 3) . That is, hGH reacts first with a receptor by using site 1 and then with a second receptor by using site 2. The basis for proposing this mechanism was that mutations in site 2 do not have an impact on the ability to form 1:1 complexes with hGH, whereas mutations in site 1 do.
The structure provided additional support for the sequential dimerization model (15) . For example, the contact epitope between hGH and hGHbp 1 buried about 1300 Å 2 , whereas that for hGH with hGHbp 2 buried only Ϸ850 Å 2 . If, however, hGHbp 2 binds to the hGH⅐hGHbp 1 complex, then 1350 Å 2 becomes buried-850 Å 2 for the hGH⅐hGHbp 2 interface plus 500 Å 2 for the hGHbp 1 ⅐hGHbp 2 interface. Thus, the binding of hGHbp 2 requires prior binding of hGHbp 1 because its binding site is composed of determinants from site 2 on hGH as well as the stem portion of the bound hGHbp 1 . The reason that the hormone does not form higher oligomers with the receptor is that the receptor uses virtually the same site to bind either site 1 or site 2 on hGH (15) . Thus, one receptor can bind only one hormone molecule at a time.
On the basis of this sequential dimerization mechanism and the structure of the complex it was possible to explain the bell-shaped dose-response curve for activation of receptors by hGH (24) (25) (26) . At low concentrations, hGH can bind to receptors and easily find an empty receptor to form a dimer and effect a signal. However, at high concentrations receptors become occupied to greater extents as 1:1 complexes, and thus fewer empty receptors are available to dimerize.
This principle of sequential assembly may be general to other hormonereceptor complexes for the simple reason that it reduces the degrees of freedom for association (for general review see ref. 27 ). In the hGH mechanism, the hormone needs only to diffuse once in three dimensions to reach the first receptor. The next association event occurs in the membrane, which is two-dimensional. Furthermore, because the receptor is tethered by its transmembrane domain this further limits two of the three degrees of rotational freedom for the receptors to dimerize.
Contrast the sequential 1:2 dimerization model with one in which two separate hormone molecules need to bind to dimerize and signal (a 2:2 model, ref. 21 ). In this case, two three-dimensional diffusion events would be required. The second membrane diffusion event would be similar except that a 1:1 hormone-receptor complex would require finding another loaded receptor. For both steps, forming a 2:2 complex is far less efficient than forming a 1:2 complex.
A bell-shaped dose-response curve, which is consistent with formation of 1:2 complexes, may be difficult to see in other hormone͞receptor systems. To observe the inhibitory phase requires extremely high hormone concentrations. Some hormones may not be readily available or even soluble at the concentrations required. Even for hGH, the half-maximal inhibitory concentration (IC 50 ) occurs at Ϸ2 M, whereas the half-maximal excitatory concentration (EC 50 ) is 20 pM. This 10,000-fold difference can be rationalized if the step to dimerize and signal is much more efficient than the initial binding event. In other words, it is difficult to saturate the receptors as 1:1 complexes before some have dimerized. Furthermore, the difference between EC 50 and IC 50 will be further expanded if only a small number of receptors need to dimerize in order to signal (25) .
Mathematical models to describe the oligomerization reactions on cell membranes with the appropriate dimensional constraints would be of use in trying to deconvolute dose-response data in terms of oligomerization parameters. Among other factors, the dimerization reaction will depend on receptor concentration or tendency for the receptor to preassociate, as well as on the association rate for the 1:1 hormone-receptor complex (25) . These parameters will surely vary from one cell type to another and from one hormone͞ receptor system to another. For these reasons and perhaps more, it may be difficult to observe a bell-shaped dose-response curve. Such behavior applies to receptor systems which form homodimers; heterodimeric (or oligomeric) systems where the hormone has a single site for two different receptors and binds them sequentially may not be antagonized by high hormone concentrations because saturating the first receptor would not reduce binding of the second.
The sequential dimerization mechanism predicted that antagonists of hGH could be produced by allowing (or enhancing) binding by site 1 while preventing dimerization by site 2 (24). Indeed, potent antagonists of hGH have been generated by introducing a mutation (G120R) into site 2 that blocks dimer formation (24, 28) . This same strategy has been used to create antagonists to the prolactin receptor based on hGH or a homolog, human placental lactogen (29) .
As the literature accumulates on other helical cytokines it is becoming apparent that a number of their receptors such as those for interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage (GM)-CSF, and erythropoietin undergo ligand-induced receptor homo-or heterooligomerization (for reviews see refs. 23, 24, and 30). Moreover, mutational analyses of the monomeric cytokines IL-2 (31), IL-3 (32, 33), IL-4 (34), GM-CSF (35, 36) , , and IL-6 (37) suggest they may have at least two receptor binding sites, a circumstance that has allowed the generation of hormone antagonists for IL-2, IL-3, IL-4, and GM-CSF.
Conclusions
The helical cytokines and their cognate receptors form a family of related structures and likely share a common binding mechanism. Each hormone has at least two sites for binding and oligomerizing its receptor(s). Such stoichiometry economizes on the diffusion events-after diffusion to the first membrane-bound receptor the second reaction with a receptor is facilitated by diffusion in two dimensions instead of three. This mechanism should provide a common strategy for generating antagonists to these hormones. That is, one can produce hormone variants that allow the first binding reaction but prevent downstream binding reactions. Such antagonists may be useful in disease states where excessive hormone levels are a problem, such as in the case of acromegaly produced by excessive levels of growth hormone.
The growth hormone receptor interfaces are large, but only a few residues are critical in binding. The interface generally resembles the core of a folded protein: well-packed hydrophobic contacts are crucial and they are inside, while hydrophilic interactions appear less important and they are outside. Although the polar residues appear less important for affinity, they may be important for solubility of the hormone and for specificity of the binding interaction. We believe the implications of these findings are important for rational drug design. Perhaps small molecules can be built to bind to these large interfaces if they are designed to bind the small functional epitopes.
Are these findings general to proteinprotein interactions? Structures of antibody-antigen complexes show these interfaces to be large and it is likely that only a small number of contact side chains are important in binding [see Davies and Cohen review in this issue (38) ]. Trapped water molecules are also present at these interfaces, whose functional importance has yet to be determined. Although charged and polar side chains can be critical in binding, it is noted that hydrophobic side chains in these and other protein-protein complexes [see Jones and Thornton review in this issue (39) ] are very important. Whether these findings are general to most protein-protein interfaces remains an open question-one that will surely be tested as more complexes are brought to the same level of structural and functional understanding.
